Zelira Therapeutics has advanced its HOPE autism drug program following a meeting with the US Food and Drug Administration.

The FDA provided a clear and positive written response to preliminary questions submitted by Zelira ahead of the meeting.

The FDA's response offered crucial clarity on treatment indications for irritability associated with autism spectrum disorder in patients with Phelan-McDermid Syndrome and Smith-Magenis Syndrome.